Who Paid My Doc
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure
Research payments
$13,593,114
Through program year 2025, $13,593,114 in research payments was reported against a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure, across 251 payments, paid by AstraZeneca Pharmaceuticals LP.
- Paid by
- AstraZeneca Pharmaceuticals LP
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $9,321,260 | 147 |
| 2024 | Research | $4,271,854 | 104 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Alvin Griffin Conyers, GA Named on 3 payments
- Scott Kuennen Kansas City, MO Named on 3 payments
- Rajesh Yalavarthy Arvada, CO Named on 3 payments
- Donald Hurley Charleston, SC Named on 3 payments
- Arvind Madan Orlando, FL Named on 3 payments
- Fahd Al-Saghir Pontiac, MI Named on 3 payments
- Abdur Baig Hollywood, FL Named on 3 payments
- Obadias Marquez Ooltewah, TN Named on 3 payments
- Jany Moussa Wichita, KS Named on 3 payments
- Frank Eder Binghamton, NY Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.